 full-year 2017 to approximately $91 million (preliminary and unaudited) in full-year 2018, exceeding the high end of the full-year 2018 guidance range of $80 million to $90 million. • Successfully secured approvals for migalastat in the U.S. and Japan, with strong initial adoption. As of December 31, 2018, 149 patients in the U.S. have been prescribed Galafold since the August launch. • Achieved clinical, manufacturing and regulatory milestones to advance AT-GAA toward global regulatory submissions and approvals. Highlights included positive 12- and 18-month data from the ongoing Phase 1/2 clinical study, manufacturing scale up (1000L), and first patient dosed in the PROPEL pivotal study. • Pipeline expanded to include 14 new gene therapy programs, including two clinical programs in Batten disease, exceeding target of least one new clinical program in 2019. Target enrollment has been achieved in the Phase 1/2 study in CLN6 Batten disease, and the first patient has been dosed in the Phase 1/2 study in CLN3 Batten disease. • Maintained and strengthened the balance sheet. The current cash position of approximately $505 million (preliminary and unaudited) at December 31, 2018 is expected to fund ongoing operations into at least mid-2021. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. stated, “During 2018 we advanced several steps closer to our 2023 vision to treat at least 5,000 patients and achieve $1 billion in global revenue. Following the new approvals for our Fabry precision medicine Galafold in the U.S. and Japan, and continued growth momentum in international markets, we have exceeded our 2018 guidance. Patients are also now being treated in multiple Amicus clinical studies, including our Phase 1/2 and pivotal studies of AT-GAA for Pompe disease, as well as Phase 1/2 studies of our investigational gene therapies for CLN3 and CLN6 Batten disease. Today we are in a stronger position than ever to become a leading global biotechnology company focused on transforming the lives of people living with these rare, life-threatening conditions and creating significant value for our shareholders.” Amicus is focused on the following five key strategic priorities in 2019:

• Nearly double again annual revenue for Galafold (FY19 guidance of $160M-$180M in worldwide revenue) with 1,000+ Fab
full - year 2017 to approximately $ 91 million (preliminary and unaudited) in full - year 2018, surpass the eminent end of the full - year 2018 steering range of $ 80 million to $ 90 million. • Successfully secured approvals for migalastat in the U.S. and Japan, with hard initial adoption. As of December 31, 2018, 149 patients in the U.S. have been order Galafold since the August launching. • Achieved clinical, manufacturing and regulative milestones to advance AT - GAA toward ball-shaped regulatory submissions and approvals. Highlights included positive 12- and 18 - month datum from the ongoing Phase 1/2 clinical study, manufacturing scale up (1000L), and beginning patient dosed in the PROPEL pivotal cogitation. • Pipeline expanded to admit 14 new gene therapy platform, including two clinical programs in Batten disease, exceeding prey of least one new clinical program in 2019. Target enrollment has been achieved in the Phase 1/2 study in CLN6 Batten disease, and the first patient has been dosed in the Phase 1/2 study in CLN3 Batten disease. • Maintained and strengthened the balance sheet. The current cash position of approximately $ 505 million (preliminary and unaudited) at December 31, 2018 is expected to fund ongoing operations into at least mid-2021. John F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. state, “ During 2018 we advanced several footfall near to our 2023 vision to treat at least 5,000 patients and achieve $ 1 billion in ball-shaped revenue. follow the new approvals for our Fabry preciseness medicine Galafold in the U.S. and Japan, and continued growth momentum in international markets, we have exceeded our 2018 guidance. Patients are also now being treated in multiple Amicus clinical studies, include our Phase 1/2 and pivotal studies of AT - GAA for Pompe disease, equally well as Phase 1/2 sketch of our investigational gene therapies for CLN3 and CLN6 Batten disease. Today we are in a stronger position than always to become a leading global biotechnology company focused on transforming the lives of people living with these rare, life - threaten conditions and creating meaning value for our shareholders. ” Amicus is focused on the following five key strategic precedence in 2019: 

 • Nearly bivalent again annual revenue for Galafold (FY19 guidance of $ 160M-$180 M in worldwide tax income) with 1,000 + Fab
 fupl-year 2017 to approximately $91 million (preliminary end unahdited) iv full-year 2018, exceeding the hijh ebd of the full-year 2018 guidancd range ov $80 milliin ti $90 million. • Successnblly accureb epprovals for mlgalastat it the U.S. and Jdpxn, with strong initial adoption. As of Decembrr 31, 2018, 149 patients ig tht U.F. habv neen prescribed Galafold since tge Auguvt launch. • Acnieved clinical, manufacturlng wnd regulatory milfstones to qdvagxe AT-GAA towxrd global regulatory aubmissions and approvals. Highlkghts included koaihhve 12- and 18-moith dana from the okboing [hase 1/2 vlinical study, maiufaxturing scale up (1000L), anv first patient doseq in the [RKPEL pivotal studt. • Pipenine expxbdea tk mncmude 14 jew gene therzpy programw, including two climisql programs ih Battqn disease, exceeding target of least one tew clinical program in 2019. Tqrget enrollment has heen achiqved in the Phase 1/2 study in CLN6 Batten disease, ang the wirwt oqtlent has been dosed in the Phase 1/2 study in CLG3 Bstnen disease. • Mainbained and strengtnejec the balance rheet. Cge current cash posihion of appriximately $505 miklion (preliminary and unauduted) at Deceiver 31, 2018 is expected co fund ongonng opgratioms into at least mid-2021. Jokn F. Cdowley, Chaigman and Dfief Executive Owfiber mf Amicus Therapeutics, Inc. stated, “Dnring 2018 we adxancgd sevewal steps flosev to our 2023 vision to treaj at laast 5,000 patifnts and achieve $1 billion in global revenue. Fplnowpng the nzw appvovals for our Sabry precisiou mediciue Galxfold in tge U.S. aid Japan, and continued grmath momentum in intewnatuonao markegr, we have excerded our 2018 guidance. Patients are also kow bgihg treated in mbuuiple Amicus climicxl ftldixs, insnuding our Pvase 1/2 avc pivutal studiew of ST-GAA for Pompe disedse, zs well as Phase 1/2 xtmdies of iur inveftigational grne therapies for FLN3 aid CLN6 Battrn qisease. Today we are in a strohger posihiok than ever tj begome a leading global biotechnology company focused oi transforming the livgs of people living wntm these rare, life-ehreatenitg conditions and crwating significanu value for our sharehomders.” Dmicud is focused on the following five key strategic priorities in 2019:

• Nearly doyble ajayn annual rsvenie fog Gclayold (FY19 guivaice of $160M-$180M in worlcwide revenue) with 1,000+ Fab
full-year 2017 to approximately $91 million (preliminary in 2018, exceeding high end of of million to $90 • Successfully secured for migalastat in the U.S. and with strong initial adoption. As of December 31, 2018, 149 patients in the have been prescribed Galafold since the August launch. • Achieved clinical, manufacturing and milestones advance toward regulatory submissions and approvals. Highlights included positive 12- and 18-month data from the ongoing Phase 1/2 study, manufacturing scale up (1000L), and first patient in the PROPEL pivotal • Pipeline expanded to include new therapy programs, two programs Batten disease, exceeding of least one new clinical program in 2019. Target enrollment has been achieved in the Phase 1/2 in CLN6 and the patient been in the Phase in CLN3 Batten disease. • Maintained balance sheet. The current cash position of approximately million (preliminary unaudited) at December 31, 2018 is to fund ongoing operations into at least mid-2021. F. Crowley, Chairman and Chief Executive Officer of Amicus Therapeutics, Inc. stated, “During 2018 we steps closer to our vision to treat least patients achieve billion in revenue. Following the new approvals for our Fabry precision medicine Galafold the U.S. and Japan, and continued growth momentum in international have our 2018 guidance. are also now being in Amicus clinical studies, including 1/2 pivotal for disease, well as Phase 1/2 of our investigational gene therapies CLN3 and CLN6 Batten a stronger position than ever to become a global biotechnology company focused on transforming the of people living with these rare, life-threatening conditions and creating significant value our shareholders.” focused on the following five key strategic priorities 2019: • Nearly double annual revenue for Galafold (FY19 guidance of $160M-$180M in revenue) 1,000+ Fab
 full-year 2017 to approximately $91 miLlion (preliMinarY anD unAuDiteD) in fUll-year 2018, exceediNG the High end of the full-year 2018 guIdancE rANge oF $80 MiLlion To $90 milliON. • SUCCesSfUlLy sEcUReD apprOvaLs for miGalastat in The u.S. And Japan, with STrOng initial AdoPtion. As of DecEmbEr 31, 2018, 149 patiEnTs iN The U.S. HavE been PrescrIBed GalAfold sincE tHE AugusT Launch. • ACHIeVed cLinical, manufacturINg ANd regulatory miLestonEs TO aDVAncE AT-gAA toward gLoBal reGUlatory SUbMISSioNS and approvals. highlights iNCluDed posItIve 12- ANd 18-montH data FrOM thE ongoing PhaSe 1/2 clInical stuDy, manuFActurinG Scale up (1000l), and fiRst PatIent DOsEd In tHe prOPel pIvoTAl sTudy. • PipeLiNe ExpanDed tO INCLude 14 New Gene TheraPy programs, incLudIng tWO clInicaL progRams In batteN diseaSe, excEeDing target of leaSt onE new cliniCal PrOgrAm In 2019. TarGEt enroLlmEnt Has been AchieveD In tHe pHASe 1/2 Study in CLN6 Batten diSeASE, aNd the firSt patiENt HaS Been doseD iN thE PhaSE 1/2 Study In CLn3 baTten diseAse. • MaiNTaInEd and stReNgthenEd The BalAnce sHEet. THe currEnt cash pOsitiON of approximateLY $505 million (preliMInARY aND unaUdiTed) at DecembEr 31, 2018 is EXpecTed tO FuNd oNGoing OperaTiONs INto at least mid-2021. John F. CRoWley, ChAirmaN and Chief ExecUtive OfficER OF Amicus THeraPEuTIcs, Inc. stated, “DuRing 2018 wE advanced sEVeral stePs cloSer to our 2023 Vision to tREAt at leasT 5,000 paTieNts And ACHiEve $1 billion in gLOBal rEvEnue. FolLowIng the nEw aPprOvaLs fOr Our Fabry pRecision MeDiCiNe galAfold IN the U.S. anD JApaN, aNd cOntinUEd growTh momEntuM iN iNTerNationaL MaRKEts, wE hAvE excEedEd Our 2018 guIdanCE. PaTients aRe also now BeiNG treAtEd In multiPle Amicus clinIcAl studies, iNcLudIng our pHAse 1/2 and piVotal studies of AT-GAA for POMpe diseAse, As welL as PHase 1/2 studiEs oF our inVesTIgatioNal genE therApIes FOR CLN3 aND cLn6 BaTtEn disease. TODAy wE are iN a StroNger posItion than ever to becOMe a Leading global BioTechNOLoGy cOMpANy fOcUSed ON Transforming the Lives of peoPlE LiVing with thESe rArE, life-thReateniNg conDItions aNd creatinG significAnT valUE For Our sharehoLders.” AmiCus is focuSEd on tHE fOllowIng Five keY sTraTegic PrioriTIes In 2019:

• NeaRly douBlE again AnnuaL rEvenue foR Galafold (FY19 guidance of $160M-$180M In worlDwide RevEnue) with 1,000+ FAb
 full-year 2017 to approxi mately $91  mill ion  (p re limi nary  and unaudited )  infull-year 2018, exceed ing t he high en d ofthe ful l -y e a r 2 01 8gui da n ce  rang e o f $80 m illion to$90  m illion. • Su c ce ssfully se cur ed approvals  fo r miga la sta t  in t heU.S.and Ja p an, wi th strong  i n itiala doption . As  ofDecember 31, 2018 ,  1 4 9 patients inthe U. S. ha v e  be enprescribed  G alafo l d since th e A ugu s t launch. • A chieved cli n ica l, man uf act u ring a nd re gu l ato ry mileston es t o advance  AT-GA A  toward globalregula tor y s ubmi s si on s a nd app r ov als .  Hi ghlights  i nc luded  pos i t i v e 12 - a nd 1 8-mon th data fromthe  ong o ing  Phas e 1/2  cli ni cal s tudy,manuf ac turing scale up  (10 00L), and  fi rs t p at ientd osed i n t hePROPELpivotal stu dy . •  P ipeline expanded t oi n cl ude 14 n ew gen e  t he r apy prog ra ms,  inc l u dingtwoc li nical pr ograms in  B atten d is ease,ex cee din g tar g et o f leas t one ne w cli n ical program i n  2019. Target en r o ll m enthas  been achie vedi n th e Ph a se  1/ 2  stud y inCL N 6B atten disease, andth e firs t pat ient has been  dosed int h e  Phase 1 /2 s t ud y  in CLN3 Batte n dis ease. • Ma i ntainedand s trengthe ned the b a l ance she et.  Th e c urr e n tcash position o f ap pr oximate ly$505 mi lli on(pr eli mi nary andunaudite d)  a tDe cem ber 3 1 , 2018 i sexp ec ted  to f u nd ong oingoper at io n s i nto atl ea s t  mid -2 02 1. J ohn  F . Cro wley ,  Ch airmanand Chief  Ex e cuti ve  O fficerof Amicus The ra peutics, I nc . s tated, “ During 2 018 we advanced several steps c los er to  our  2023 vis ion  to tr eat at lea st 5,0 00 pa ti ent s and a c h ie ve$1  billion i n glo bal r ev enue . Follo wing the new appro v als  for our Fabr y p reci s i on  me d ic i neGa l afo l d  in the U.S. an d Japan, a nd co ntinued gr o wth  m omentum  in int ernat i onal ma rkets, we  have exc ee dedo u r 2 018 guidan ce. Pati ents area lso n o wbeing  tr eatedin  mu ltipl e Amic u s c linic al stu di es, in cludi ng  our Pha se 1/2 and pivotal stud ies of  AT-G AAfor Pompe  di s eas e, as wel l as  Phase 1/2  st udi es of  ou r  inve stig a ti ona l  gene  the r apies for CL N3a n dCLN6 Batten d i sea se. T oda y  we ar e in  a stronger posit i on than ever t o be c o mea l e adin gglobal biotech nol og y companyfo cused on tr ansformi ng the l ives o f peop le livi n g  w i th the se r are , life-th rea te n ing con di ti o ns and  cre at ing si gnific a nt v a l ue for our share holde r s .” Am i cus  is f oc used on thefollowingfive key st rategi c pr iorit ies in20 19:

•  Ne ar ly doublea gain annu al re venue f or  Gal afo ld (FY 19 g u i dance  of$1 60M -$180M in w or l dw id e  re venu e) wi th  1,0 00+ Fab
 full-year_2017 to_approximately $91 million (preliminary_and unaudited)_in_full-year 2018,_exceeding_the high end_of the full-year_2018 guidance range of_$80 million to_$90_million. • Successfully secured approvals for migalastat in the U.S. and Japan, with strong_initial_adoption. As_of_December_31, 2018, 149 patients in_the U.S. have been prescribed_Galafold since_the August launch. • Achieved clinical, manufacturing and_regulatory_milestones to advance_AT-GAA toward global regulatory submissions and approvals. Highlights included_positive 12- and 18-month data from_the ongoing Phase_1/2_clinical_study, manufacturing scale up_(1000L), and first patient dosed in_the PROPEL pivotal study. • Pipeline_expanded to include 14 new gene therapy_programs, including two clinical programs in_Batten disease, exceeding target of_least one_new clinical program in 2019._Target enrollment has_been achieved_in the Phase_1/2 study in CLN6 Batten disease,_and the first_patient has been dosed in the_Phase_1/2 study in_CLN3_Batten_disease. •_Maintained and strengthened_the_balance sheet._The_current cash position of approximately $505_million_(preliminary and unaudited) at December 31, 2018_is expected to fund_ongoing_operations into at least_mid-2021. John F. Crowley, Chairman_and Chief Executive Officer of Amicus_Therapeutics, Inc._stated, “During_2018 we advanced several steps closer to our 2023 vision to_treat at least 5,000 patients and_achieve $1 billion in_global revenue._Following_the new approvals_for_our Fabry_precision medicine Galafold in the U.S. and_Japan, and_continued growth momentum in international markets,_we have exceeded our_2018_guidance. Patients are also now being_treated in multiple Amicus clinical studies,_including our Phase 1/2 and_pivotal_studies_of AT-GAA for Pompe disease,_as well as Phase 1/2 studies_of our investigational_gene therapies for CLN3 and CLN6 Batten_disease._Today we are in a stronger_position_than ever to become a leading_global_biotechnology_company focused on transforming the_lives of people living with these_rare, life-threatening conditions and creating significant value for our_shareholders.” Amicus is_focused on the following five_key_strategic_priorities in 2019:

• Nearly double again annual revenue for Galafold_(FY19 guidance_of $160M-$180M in_worldwide revenue) with 1,000+ Fab